Progress in Islet Transplantation in Patients with Type 1 Diabetes Mellitus

Minkowski O. Untersuchungen uber den diabetes mellitus nac exgtirpation der pankreas. Berl Klin Wschr 1892; 29: 90–3 Williams P. Notes on diabetes treated with extract and by grafts of sheep’s pancreas. BMJ 1894; 2: 1303–4 Banting F. Extract from Banting’s notebook 2am October 31st: Academy of Medicine notebook. Toronto (ON): Archives of Toronto University, 1920 Kelly WD, Lillehei RC, Merkel FK, et al. Allotransplantation of the pancreas and duodenum along with the kidney in diabetic nephropathy. Surgery 1967; 61(6): 827–37 Lacy PE, Kostianovsky M. Method for the isolation of intact islets of Langerhans from the rat pancreas. Diabetes 1967; 16(1): 35–9 Ballinger WF, Lacy PE. Transplantation of intact pancreatic islets in rats. Surgery 1972; 72(2): 175–86 Sutherland DE, Gruessner RW, Dunn DL, et al. Lessons learned from more than 1000 pancreas transplants at a single institution. Ann Surg 2001; 233(4): 463–501 Tosatti E, Valente U, Campisi C, et al. Segmental pancreas autotransplantation in man following total or near total pancreatectomy for serious recurrent chronic pancreatitis. Transplant Proc 1980; 12(4 Suppl. 2): 15–8 Valente U, Ferro M, Campisi C, et al. Report of clinical cases of islet autotransplantation. Transplant Proc 1980; 12(4 Suppl. 2): 202–4 Valente U, Ferro M, Campisi C, et al. Allogeneic pancreatic islet transplantation by means of artificial membrane chambers in 13 diabetic recipients. Transplant Proc 1980; 12(4 Suppl. 2): 223–6 Najarian JS, Sutherland DE, Matas AJ, et al. Human islet transplantation: a preliminary report. Transplant Proc 1977; 9(1): 233–6 Sutherland DE, Matas AJ, Goetz FC, et al. Transplantation of dispersed pancreatic islet tissue in humans: autografts and allografts. Diabetes 1980; 29Suppl. 1: 31–44 Largiader F, Kolb E, Binswanger U, et al. Successful allotransplantation of an island of Langerhans. Schweiz Med Wochenschr 1979; 109(45): 1733–6 Kolb E, Largiader F. Clinical islet transplantation. Transplant Proc 1980; 12(4 Suppl. 2): 205–7 Gray DW, McShane P, Grant A, et al. A method for isolation of islets of Langerhans from the human pancreas. Diabetes 1984; 33(11): 1055–61 Ricordi C, Lacy PE, Scharp DW. Automated islet isolation from human pancreas. Diabetes 1989; 38Suppl. 1: 140–2 Lake SP, Bassett PD, Larkins A, et al. Large-scale purification of human islets utilizing discontinuous albumin gradient on IBM 2991 cell separator. Diabetes 1989; 38Suppl. 1: 143–5 Robertson GS, Chadwick DR, Contractor H, et al. The optimization of large-scale density gradient isolation of human islets. Acta Diabetol 1993; 30(2): 93–8 Scharp DW, Lacy PE, Santiago JV, et al. Insulin independence after islet transplantation into type I diabetic patient. Diabetes 1990; 39(4): 515–8 Scharp DW, Lacy PE, Santiago JV, et al. Results of our first nine intraportal islet allografts in type 1, insulin-dependent diabetic patients. Transplantation 1991; 51(1): 76–85 Tzakis AG, Ricordi C, Alejandro R, et al. Pancreatic islet transplantation after upper abdominal exenteration and liver replacement. Lancet 1990; 336(8712): 402–5 Farney AC, Najarian JS, Nakhleh RE, et al. Autotransplantation of dispersed pancreatic islet tissue combined with total or near-total pancreatectomy for treatment of chronic pancreatitis. Surgery 1991; 110(2): 427–37; discussion 437-9 Socci C, Falqui L, Davalli AM, et al. Fresh human islet transplantation to replace pancreatic endocrine function in type 1 diabetic patients: report of six cases. Acta Diabetol 1991; 28(2): 151–7 Gores PF, Najarian JS, Stephanian E, et al. Insulin independence in type I diabetes after transplantation of unpurified islets from single donor with 15-deoxyspergualin. Lancet 1993; 341(8836): 19–21 Jaeger C, Hering BJ, Dyrberg T, et al. Islet cell antibodies and glutamic acid decarboxylase antibodies in patients with insulin-dependent diabetes mellitus undergoing kidney and islet-after-kidney transplantation. Transplantation 1996; 62(3): 424–6 Brendel MD, Hering BJ, Schultz AO, et al. International Islet Transplant Registry report, newsletter #8. Giessen: University of Giessen, 1999 Alejandro R, Lehmann R, Ricordi C, et al. Long-term function (6 years) of islet allografts in type 1 diabetes. Diabetes 1997; 46(12): 1983–9 Bretzel RG, Brandhorst D, Brandhorst H, et al. Improved survival of intraportal pancreatic islet cell allografts in patients with type-1 diabetes mellitus by refined peritransplant management. J Mol Med 1999; 77(1): 140–3 Shapiro AM, Lakey JR, Ryan EA, et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 2000; 343(4): 230–8 Shapiro AM, Ricordi C, Hering B. Edmonton’s islet success has indeed been replicated elsewhere [letter]. Lancet 2003; 362(9391): 1242 Ault A. Edmonton’s islet success tough to duplicate elsewhere [letter]. Lancet 2003; 361(9374): 2054 Lakey JR, Cavanagh TJ, Zieger MA, et al. Evaluation of a purified enzyme blend for the recovery and function of canine pancreatic islets. Cell Transplant 1998; 7(4): 365–72 Linetsky E, Bottino R, Lehmann R, et al. Improved human islet isolation using a new enzyme blend, liberase. Diabetes 1997; 46(7): 1120–3 Horaguchi A, Merrell RC. Preparation of viable islet cells from dogs by a new method. Diabetes 1981; 30(5): 455–8 Lakey JR, Warnock GL, Shapiro AM, et al. Intraductal collagenase delivery into the human pancreas using syringe loading or controlled perfusion. Cell Transplant 1999; 8(3): 285–92 Scharp DW, Kemp CB, Knight MJ, et al. The use of Ficoll in the preparation of viable islets of Langerhans from the rat pancreas. Transplantation 1973; 16(6): 686–9 Olack B, Swanson C, McLear M, et al. Islet purification using Euro-Ficoll gradients. Transplant Proc 1991; 23(1 Pt 1): 774–6 Ricordi C, Lacy PE, Finke EH, et al. Automated method for isolation of human pancreatic islets. Diabetes 1988; 37(4): 413–20 Latif ZA, Noel J, Alejandro R. A simple method of staining fresh and cultured islets. Transplantation 1988; 45(4): 827–30 Scharp D, Lacy P, Ricordi C, et al. Human islet transplantation in patients with type I diabetes. Transplant Proc 1989; 21 (1 Pt 3): 2744–5 Warnock GL, Kneteman NM, Ryan EA, et al. Continued function of pancreatic islets after transplantation in type I diabetes. Lancet 1989; II(8662): 570–2 McAlister VC, Gao Z, Peltekian K, et al. Sirolimus-tacrolimus combination immunosuppression. Lancet 2000; 355(9201): 376–7 Shapiro AM, Geng Hao E, Lakey JR, et al. Defining optimal immunosuppression for islet transplantation based on reduced diabetogenicity in canine islet autografts. Transplantation 2002; 74(11): 1522–8 Birkeland SA, Beck-Nielsen H, Rohr N, et al. Steroid-free immunosuppression in kidney-islet transplantation: a long-term follow-up [letter]. Transplantation 2002; 73(9): 1527; author reply 1528 Rabinovitch A, Suarez-Pinzon WL. Cytokines and their roles in pancreatic islet beta-cell destruction and insulin-dependent diabetes mellitus. Biochem Pharmacol 1998; 55(8): 1139–49 Brattstrom C, Wilczek H, Tyden G, et al. Hyperlipidemia in renal transplant recipients treated with sirolimus (rapamycin). Transplantation 1998; 65(9): 1272–4 Morrisett JD, Abdel-Fattah G, Hoogeveen R, et al. Effects of sirolimus on plasma lipids, lipoprotein levels, and fatty acid metabolism in renal transplant patients. J Lipid Res 2002; 43(8): 1170–80 Kneteman NM, Lakey JR, Wagner T, et al. The metabolic impact of rapamycin (sirolimus) in chronic canine islet graft recipients. Transplantation 1996; 61(8): 1206–10 Rother KI, Harlan DM. Challenges facing islet transplantation for the treatment of type 1 diabetes mellitus. J Clin Invest 2004; 114(7): 877–83 Ryan EA, Paty BW, Senior PA, et al. Risks and side effects of islet transplantation. Curr Diab Rep 2004; 4(4): 304–9 Fiorina P, Gremizzi C, Maffi P, et al. Islet transplantation is associated with an improvement of cardiovascular function in type 1 diabetic kidney transplant patients. Diabetes Care 2005; 28(6): 1358–65 Fiorina P, Venturini M, Folli F, et al. Natural history of kidney graft survival, hypertrophy, and vascular function in end-stage renal disease type 1 diabetic kidney-transplanted patients: beneficial impact of pancreas and successful islet cotransplantation. Diabetes Care 2005; 28(6): 1303–10 Schmied BM, Ulrich A, Matsuzaki H, et al. Maintenance of human islets in long-term culture. Differentiation 2000; 66(4-5): 173–80 Hering BJ, Kandaswamy R, Harmon JV, et al. Transplantation of cultured islets from two-layer preserved pancreases in type 1 diabetes with anti-CD3 antibody. Am J Transplant 2004; 4(3): 390–401 Goss JA, Schock AP, Brunicardi FC, et al. Achievement of insulin independence in three consecutive type-1 diabetic patients via pancreatic islet transplantation using islets isolated at a remote islet isolation center. Transplantation 2002; 74(12): 1761–6 Matsumoto S, Qualley SA, Goel S, et al. Effect of the two-layer (University of Wisconsin solution-perfluorochemical plus O2) method of pancreas preservation on human islet isolation, as assessed by the Edmonton Isolation Protocol. Transplantation 2002; 74(10): 1414–9 Ricordi C, Fraker C, Szust J, et al. Improved human islet isolation outcome from marginal donors following addition of oxygenated perfluorocarbon to the cold-storage solution. Transplantation 2003; 75(9): 1524–7 Birkeland SA, Beck-Nielsen H, Rohr N, et al. Islet and kidney transplantation using ATG and cyclosporin monotherapy and a central facility for islet isolation and purification. Transplant Proc 1995; 27(6): 3150–7 Shapiro AM, Lakey JR, Paty BW, et al. Strategic opportunities in clinical islet transplantation. Transplantation 2005; 79(10): 1304–7 Ryan EA, Paty BW, Senior PA, et al. Five-year follow-up after clinical islet transplantation. Diabetes 2005; 54(7): 2060–9 Ryan EA, Lakey JR, Paty BW, et al. Successful islet transplantation: continued insulin reserve provides long-term glycemic control. Diabetes 2002; 51(7): 2148–57 Johnson JA, Kotovych M, Ryan EA, et al. Reduced fear of hypoglycemia in successful islet transplantation. Diabetes Care 2004; 27(2): 624–5 Fiorina P, Folli F, Maffi P, et al. Islet transplantation improves vascular diabetic complications in patients with diabetes who underwent kidney transplantation: a comparison between kidney-pancreas and kidney-alone transplantation. Transplantation 2003; 75(8): 1296–301 Fiorina P, Folli F, Zerbini G, et al. Islet transplantation is associated with improvement of renal function among uremic patients with type I diabetes mellitus and kidney transplants. J Am Soc Nephrol 2003; 14(8): 2150–8 Shapiro AM. Islet transplants and impact on secondary diabetic complications: does C-peptide protect the kidney? J Am Soc Nephrol 2003; 14(8): 2214–6 Ryan EA, Paty BW, Senior PA, et al. Beta-score: an assessment of beta-cell function after islet transplantation. Diabetes Care 2005; 28(2): 343–7 Couzin J. Diabetes. Islet transplants face test of time. Science 2004; 306(5693): 34 Frank A, Deng S, Huang X, et al. Transplantation for type I diabetes: comparison of vascularized whole-organ pancreas with isolated pancreatic islets. Ann Surg 2004; 240(4): 631–40; discussion 640-3 Ryan EA, Lakey JR, Rajotte RV, et al. Clinical outcomes and insulin secretion after islet transplantation with the Edmonton protocol. Diabetes 2001; 50(4): 710–9 Davalli AM, Ogawa Y, Scaglia L, et al. Function, mass, and replication of porcine and rat islets transplanted into diabetic nude mice. Diabetes 1995; 44(1): 104–11 Davalli AM, Ogawa Y, Ricordi C, et al. A selective decrease in the beta cell mass of human islets transplanted into diabetic nude mice. Transplantation 1995; 59(6): 817–20 Bennet W, Sundberg B, Groth CG, et al. Incompatibility between human blood and isolated islets of Langerhans: a finding with implications for clinical intraportal islet transplantation? Diabetes 1999; 48(10): 1907–14 Moberg L, Johansson H, Lukinius A, et al. Production of tissue factor by pancreatic islet cells as a trigger of detrimental thrombotic reactions in clinical islet transplantation. Lancet 2002; 360(9350): 2039–45 Titus TT, Horton PJ, Badet L, et al. Adverse outcome of human islet-allogeneic blood interaction. Transplantation 2003; 75(8): 1317–22 Piemonti L, Leone BE, Nano R, et al. Human pancreatic islets produce and secrete MCP-1/CCL2: relevance in human islet transplantation. Diabetes 2002; 51(1): 55–65 Korsgren O, Nilsson B, Berne C, et al. Current status of clinical islet transplantation. Transplantation 2005; 79(10): 1289–93 Robertson RP. Islet transplantation as a treatment for diabetes: a work in progress. N Engl J Med 2004; 350(7): 694–705 Brandhorst H, Brandhorst D, Hering BJ, et al. Body mass index of pancreatic donors: a decisive factor for human islet isolation. Exp Clin Endocrinol Diabetes 1995; 103Suppl. 2: 23–6 Bertuzzi F, Garancini P, Socci TC, et al. Lessons from in vitro perifusion of pancreatic islets isolated from 80 human pancreases. Cell Transplant 1999; 8(6): 709–12 Arita S, Une S, Ohtsuka S, et al. Increased islet viability by addition of beraprost sodium to collagenase solution. Pancreas 2001; 23(1): 62–7 Matsumoto S, Rigley TH, Qualley SA, et al. Efficacy of the oxygen-charged static two-layer method for short-term pancreas preservation and islet isolation from nonhuman primate and human pancreata. Cell Transplant 2002; 11(8): 769–77 Rose NL, Palcic MM, Helms LM, et al. Evaluation of Pefabloc as a serine protease inhibitor during human-islet isolation. Transplantation 2003; 75(4): 462–6 Brandhorst H, Brandhorst D, Hesse F, et al. Successful human islet isolation utilizing recombinant collagenase. Diabetes 2003; 52(5): 1143–6 Hering BJ, Kandaswamy R, Ansite JD, et al. Single-donor, marginal-dose islet transplantation in patients with type 1 diabetes. JAMA 2005; 293(7): 830–5 Shapiro AM, Ricordi C. Unraveling the secrets of single donor success in islet transplantation. Am J Transplant 2004; 4(3): 295–8 Contreras JL, Eckstein C, Smyth CA, et al. Brain death significantly reduces isolated pancreatic islet yields and functionality in vitro and in vivo after transplantation in rats. Diabetes 2003; 52(12): 2935–42 Eckhoff DE, Eckstein C, Smyth CA, et al. Enhanced isolated pancreatic islet recovery and functionality in rats by 17beta-estradiol treatment of brain death donors. Surgery 2004; 136(2): 336–45 Goto M, Johansson H, Maeda A, et al. Low molecular weight dextran sulfate prevents the instant blood-mediated inflammatory reaction induced by adult porcine islets. Transplantation 2004; 77(5): 741–7 Moberg L, Olsson A, Berne C, et al. Nicotinamide inhibits tissue factor expression in isolated human pancreatic islets: implications for clinical islet transplantation. Transplantation 2003; 76(9): 1285–8 Titus T, Badet L, Gray DW. Islet cell transplantation for insulin-dependent diabetes mellitus: perspectives from the present and prospects for the future. Expert Rev Mol Med 2000; 2000: 1–28 Deschamps JY, Roux FA, Gouin E, et al. Reluctance of French patients with type 1 diabetes to undergo pig pancreatic islet xenotransplantation. Xenotransplantation 2005; 12(3): 175–80 Rios AR, Conesa CC, Ramirez P, et al. Public attitude toward xenotransplantation: opinion survey. Transplant Proc 2004; 36(10): 2901–5 Teran-Escandon D, Teran-Ortiz L, Ormsby-Jenkins C, et al. Psychosocial aspects of xenotransplantation: survey in adolescent recipients of porcine islet cells. Transplant Proc 2005; 37(1): 521–4 Komoda H, Miyagawa S, Omori T, et al. Survival of adult islet grafts from transgenic pigs with N-acetylglucosaminyltransferase-III (GnT-III) in cynomolgus monkeys. Xenotransplantation 2005; 12(3): 209–16 Hermann M, PirkebnerD, Draxl A, et al. In the search of potential human islet stem cells: is tetranectin showing us the way? Transplant Proc 2005; 37(2): 1322–5 Thomas D, Suthanthiran M. Optimal modes and targets of gene therapy in transplantation. Immunol Rev 2003; 196: 161–75 Halban PA. Cellular sources of new pancreatic beta cells and therapeutic implications for regenerative medicine. Nat Cell Biol 2004; 6(11): 1021–5 Chen NK, Sivalingam J, Tan SY, et al. Plasmid-electroporated primary hepatocytes acquire quasi-physiological secretion of human insulin and restore euglycemia in diabetic mice. Gene Ther 2005; 12(8): 655–67 Nakajima-Nagata N, Sakurai T, Mitaka T, et al. In vitro induction of adult hepatic progenitor cells into insulin-producing cells. Biochem Biophys Res Commun 2004; 318(3): 625–30 Zalzman M, Gupta S, Giri RK, et al. Reversal of hyperglycemia in mice by using human expandable insulin-producing cells differentiated from fetal liver progenitor cells. Proc Natl Acad Sci U S A 2003; 100(12): 7253–8 Zalzman M, Anker-Kitai L, Efrat S. Differentiation of human liver-derived, insulin-producing cells toward the beta-cell phenotype. Diabetes 2005; 54(9): 2568–75 Bulotta A, Farilla L, Hui H, et al. The role of GLP-1 in the regulation of islet cell mass. Cell Biochem Biophys 2004; 40(3 Suppl.): 65–78 Lopez-Talavera JC, Garcia-Ocana A, Sipula I, et al. Hepatocyte growth factor gene therapy for pancreatic islets in diabetes: reducing the minimal islet transplant mass required in a glucocorticoid-free rat model of allogeneic portal vein islet transplantation. Endocrinology 2004; 145(2): 467–74 Nielsen JH, Svensson C, Galsgaard ED, et al. Beta cell proliferation and growth factors. J Mol Med 1999; 77(1): 62–6 Ogawa N, List JF, Habener JF, et al. Cure of overt diabetes in NOD mice by transient treatment with anti-lymphocyte serum and exendin-4. Diabetes 2004; 53(7): 1700–5 Rooman I, Bouwens L. Combined gastrin and epidermal growth factor treatment induces islet regeneration and restores normoglycaemia in C57B16/J mice treated with alloxan. Diabetologia 2004; 47(2): 259–65 Matsumoto S, Okitsu T, Iwanaga Y, et al. Insulin independence after living-donor distal pancreatectomy and islet allotransplantation. Lancet 2005; 365(9471): 1642–4 Mittal VK, Toledo-Pereyra LH, Sharma M, et al. Acute portal hypertension and disseminated intravascular coagulation following pancreatic islet autotransplantation after subtotal pancreatectomy. Transplantation 1981; 31(4): 302–4 Shapiro AM, Lakey JR, Rajotte RV, et al. Portal vein thrombosis after transplantation of partially purified pancreatic islets in a combined human liver/islet allograft. Transplantation 1995; 59(7): 1060–3 Villiger P, Ryan EA, Owen R, et al. Prevention of bleeding after islet transplantation: lessons learned from a mulitvariate analysis of 132 cases at a single institution. Am J Transplant 2005; 5(12): 2992–8 Han D, Xu X, Baidal D, et al. Assessment of cytotoxic lymphocyte gene expression in the peripheral blood of human islet allograft recipients: elevation precedes clinical evidence of rejection. Diabetes 2004; 53(9): 2281–90 Bell E, Cao X, Moibi JA, et al. Rapamycin has a deleterious effect on MIN-6 cells and rat and human islets. Diabetes 2003; 52(11): 2731–9 Adams AB, Shirasugi N, Durham MM, et al. Calcineurin inhibitor-free CD28 blockade-based protocol protects allogeneic islets in nonhuman primates. Diabetes 2002; 51(2): 265–70 Fu F, Hu S, Deleo J, et al. Long-term islet graft survival in streptozotocin- and autoimmune-induced diabetes models by immunosuppressive and potential insulinotropic agent FTY720. Transplantation 2002; 73(9): 1425–30 Wijkstrom M, Kenyon NS, Kirchhof N, et al. Islet allograft survival in nonhuman primates immunosuppressed with basiliximab, RAD, and FTY720. Transplantation 2004; 77(6): 827–35 Herold KC, Hagopian W, Auger JA, et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med 2002; 346(22): 1692–8 Contreras JL, Jenkins S, Eckhoff DE, et al. Stable alpha- and beta-islet cell function after tolerance induction to pancreatic islet allografts in diabetic primates. Am J Transplant 2003; 3(2): 128–38